Search research articles
Contact Us
Filters
Showing results (111-120 of 195) with videos related to
Page
of 20
Sort By:
Alimentary Pharmacology & Therapeutics
|
June 8, 2020
Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study
Mark A Samaan, Georgina Cunningham, Aravind Gokul Tamilarasan, et al.
Crohn'S & Colitis 360
|
July 11, 2026
Mirikizumab is equally effective in ustekinumab-exposed and ustekinumab-naïve patients with UC: a multicenter real-world cohort
Mohmmed Tauseef Sharip, Dharmaraj Durai, Eva Vayreda, et al.
United European Gastroenterology Journal
|
June 8, 2017
Thioguanine in inflammatory bowel disease: Long-term efficacy and safety
Mark G Ward, Kamal V Patel, Viraj C Kariyawasam, et al.
Inflammatory Bowel Diseases
|
March 4, 2026
Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study
Bruce E Sands, David B Clemow, Geert D'Haens, et al.
Gastroenterology
|
June 20, 2017
A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial
Heidi Maria Staudacher, Miranda C E Lomer, Freda M Farquharson, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
July 29, 2011
Cutting Edge: Regulator of G protein signaling-1 selectively regulates gut T cell trafficking and colitic potential
Deena L Gibbons, Lucie Abeler-Dörner, Tim Raine, et al.
Gut
|
January 13, 2022
Establishment of a validated central reading system for ileocolonoscopy in an academic setting
Tim Raine, Holly Pavey, Wendi Qian, et al.
Neurogastroenterology and Motility
|
August 25, 2021
Long-term personalized low FODMAP diet improves symptoms and maintains luminal Bifidobacteria abundance in irritable bowel syndrome
Heidi M Staudacher, Megan Rossi, Thomas Kaminski, et al.
BMJ Open Gastroenterology
|
September 1, 2025
Etrasimod for the symptomatic relief of ulcerative colitis: a post-hoc analysis from the ELEVATE UC clinical programme
María Chaparro, Remo Panaccione, Bruce E Sands, et al.
Frontline Gastroenterology
|
May 19, 2020
Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response
Mark A Samaan, Siddharth Birdi, Maria Sierra Morales, et al.
Page
of 20
Search research articles
Search
Showing results (111-120 of 195) with videos related to
Sort By:
Page
of 20
Alimentary Pharmacology & Therapeutics
|
June 8, 2020
Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study
Mark A Samaan, Georgina Cunningham, Aravind Gokul Tamilarasan, et al.
Crohn'S & Colitis 360
|
July 11, 2026
Mirikizumab is equally effective in ustekinumab-exposed and ustekinumab-naïve patients with UC: a multicenter real-world cohort
Mohmmed Tauseef Sharip, Dharmaraj Durai, Eva Vayreda, et al.
United European Gastroenterology Journal
|
June 8, 2017
Thioguanine in inflammatory bowel disease: Long-term efficacy and safety
Mark G Ward, Kamal V Patel, Viraj C Kariyawasam, et al.
Inflammatory Bowel Diseases
|
March 4, 2026
Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study
Bruce E Sands, David B Clemow, Geert D'Haens, et al.
Gastroenterology
|
June 20, 2017
A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial
Heidi Maria Staudacher, Miranda C E Lomer, Freda M Farquharson, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
July 29, 2011
Cutting Edge: Regulator of G protein signaling-1 selectively regulates gut T cell trafficking and colitic potential
Deena L Gibbons, Lucie Abeler-Dörner, Tim Raine, et al.
Gut
|
January 13, 2022
Establishment of a validated central reading system for ileocolonoscopy in an academic setting
Tim Raine, Holly Pavey, Wendi Qian, et al.
Neurogastroenterology and Motility
|
August 25, 2021
Long-term personalized low FODMAP diet improves symptoms and maintains luminal Bifidobacteria abundance in irritable bowel syndrome
Heidi M Staudacher, Megan Rossi, Thomas Kaminski, et al.
BMJ Open Gastroenterology
|
September 1, 2025
Etrasimod for the symptomatic relief of ulcerative colitis: a post-hoc analysis from the ELEVATE UC clinical programme
María Chaparro, Remo Panaccione, Bruce E Sands, et al.
Frontline Gastroenterology
|
May 19, 2020
Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response
Mark A Samaan, Siddharth Birdi, Maria Sierra Morales, et al.
Page
of 20